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Tissue transglutaminase (tTG) is a GTP-binding
protein/acyltransferase whose expression is upregu-
lated in glioblastoma and associated with decreased
patient survival. Here, we delineate a unique mecha-
nism by which tTG contributes to the development of
gliomas by using two glioblastoma cell lines, U87 and
LN229, whose growth and survival are dependent on
tTG. We show that tTG significantly enhances the
signaling activity and lifespan of EGF receptors
(EGFRs) in these brain cancer cells. Moreover, over-
expressing tTG in T98G glioblastoma cells that nor-
mally express low levels of tTG caused a marked
upregulation of EGFR expression and transforming
activity. Furthermore, we show that tTG accentuates
EGFR signaling by blocking c-Cbl-catalyzed EGFR
ubiquitylation through the ability of tTG to bind GTP
and adopt a specific conformation that enables it to
interact with c-Cbl. These findings demonstrate
that tTG contributes to gliomagenesis by interfering
with EGFR downregulation and, thereby, promoting
transformation.
INTRODUCTION
Glioblastoma (GBM) multiforme, also known as GBM or grade IV
astrocytoma, represents one of the most prevalent and aggres-
sive forms of primary brain tumor that occurs in humans. GBMs
are therapeutically challenging due to the collective effects of a
number of traits frequently exhibited by these types of tumors,
including rapid growth rates, resistance to radiation and chemo-
therapy, a high recurrence rate following surgical resection, and
an ability to infiltrate surrounding normal tissue (Furnari et al.,
2007). As a result, patients with GBMs tend to survive only
12–17 months following their initial diagnosis, even despite
having received a multimodal therapy regiment (Stupp et al.,
2005). Thus, there continues to be an overriding need to develop
additional strategies to manage this devastating form of cancer.
In an effort to identify new potential targets for therapeutic
intervention, we searched for proteins whose expression is upre-
gulated in GBM and correlated with a poor patient prognosis.
One intriguing candidate that emerged is tissue transglutami-2008 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorsnase (tTG), a GTP-binding protein/acyltransferase previously
reported to be 1 of 11metastasis-associated proteins selectively
amplified in human lung and breast cancers (Jiang et al., 2003a,
2003b). tTG promotes the growth and survival of several different
cancer cell types (Kim et al., 2011; Li et al., 2010), outcomes that
are largely thought to be dependent on its acyltransferase (pro-
tein crosslinking) activity. In order to determine how tTG contrib-
utes to the development of malignant brain cancer, we used
GBM cell lines whose aberrant growth and survival are highly
dependent upon tTG. Here, we show that tTG plays an important
role in the transformed properties of these cancer cells by having
a major influence on epidermal growth factor receptor (EGFR)
protein levels and signaling activities. The ability of tTG to affect
EGFR expression and function has significant implications for
brain cancer given that this receptor tyrosine kinase has been
shown to trigger mitogenic and survival responses in both
normal astrocytes and brain tumor-derived cell lines (Lund-
Johansen et al., 1990; Rousselet et al., 2012). Moreover, ectopic
expression of the EGFR in normal cell types induces their trans-
formation in a ligand-dependent manner, suggesting that
increased signaling by the EGFR plays a critical role in promoting
human malignancies (Moscatello et al., 1996).
At the protein level, the EGFR is overexpressed in approxi-
mately 60%–90% of all GBMs, with the extent of EGFR expres-
sion being correlated with poor patient outcomes (Shinojima
et al., 2003; Umesh et al., 2009). Although amplification of the
gene encoding the EGFR can account for the aberrant EGFR
expression detected in 30%–40% of primary brain tumors or
brain tumor-derived cell lines (Guillaudeau et al., 2009; Liber-
mann et al., 1985), additional mechanisms must be involved to
account for the increased EGFR protein levels observed in those
GBM cases where gene amplification does not occur, as well as
for the excessive and sustained EGFR signaling that is charac-
teristic of these brain cancers. Thus, it seemed likely that the
disruption of the normal (negative) regulation of EGFRs contrib-
utes to the aberrant EGFR-signaling capabilities exhibited in at
least some GBMs. Indeed, it is through the regulation of EGFR
degradation where tTG appears to exert a major influence
because we show that it affects the ability of c-Cbl, an E3 ubiq-
uitin ligase, to target the EGFR for lysosomal degradation. This
involves the ability of tTG, when bound to GTP and having adop-
ted a specific GTP-induced conformational state, to associate
with c-Cbl and block the c-Cbl-catalyzed ubiquitylation and
degradation of EGFRs, thereby significantly enhancing and
extending EGFR-signaling activities.
Figure 1. tTG Expression Is Upregulated
in High-Grade Human Brain Tumors and
Correlates with Poor Patient Outcomes
(A–C) Tissue arrays of human primary brain tumors
of increasing grades and normal brain samples
were subjected to immunohistochemical analysis
using tTG, EGFR, and phospho-EGFR antibodies.
(A) Expression levels of tTG detected in the tissue
array. Each symbol on the chart represents
an individual normal brain or tumor sample as
indicated.
(B) Representative images of a normal brain
sample and a grade IV tumor (GBM) stained for
tTG. Magnification is 310.
(C) The expression levels of tTG (left) and the
EGFR (middle) and the levels of EGFR phosphor-
ylation (right) shown represent their enhanced
expression in brain tumor tissue relative to their
expression in normal brain tissue (which was
set to 1).
(D) Kaplan-Meier survival plots for patients with
GBM (left panel) and patients with glioma (right
panel) with differential tTG expression levels. Data
were cited from REMBRANDT and National Can-
cer Institute and accessed on March 18, 2013.
Downreg, downregulation; Upreg, upregulation.
See also Figure S1.RESULTS
tTG Is Overexpressed in Human Brain Tumors
tTG functions both as a GTPase and acyltransferase whose
expression and activation have been shown to be upregulated
in several different types of human cancer, including breast,
ovarian, and pancreatic cancer (Miyoshi et al., 2010; Singer
et al., 2006; Verma et al., 2006). In addition, tTG has been
demonstrated to play an important role in the growth, survival,
migration, and invasive activity of aggressive cancer cells (Li
et al., 2011). These findings, coupled with the fact that tTG was
identified as a downstream signaling partner of the EGFR,
promoting the transformed characteristics of human breast
cancer SKBR3 cells (Li et al., 2010), as well as having an essen-
tial function in the EGF-stimulated migration and invasion ofCell Reports 3, 2008–202different cancer cells (Antonyak et al.,
2009; Boroughs et al., 2011), made it
attractive to consider that tTG plays an
important role in the development of brain
cancer.
We began by examining tTG expres-
sion levels in human primary brain tu-
mors. A tissue array consisting of normal
brain tissues and astrocytomas ranging
from grade I to grade IV (grade IV astrocy-
tomas are also referred to as GBMs) was
immunostained for tTG. We found that,
like the case for the normal human astro-
cyte (NHA) controls, tTG expression in
normal brain is generally low (Figures
1A, 1B, and S1A, top panel). Similarly,tTG is often expressed at relatively low levels in the lower-grade
(grades I and II) astrocytomas (Figure 1C, left panel). However, in
the more advanced/aggressive brain tumors (i.e., grades III and
IV astrocytomas), tTG expression was frequently upregulated.
For example, greater than 80% of the grade III astrocytomas
and nearly 60% of the grade IV astrocytomas showed increased
tTG expression (Figure 1A). Figure 1B shows a representative
comparison of tTG expression in a normal brain sample versus
a grade IV astrocytoma. We then took our analysis one step
further by comparing tTG transcript levels in the four subtypes
of GBMs that have been identified according to their unique
molecular signatures (Verhaak et al., 2010) using The Cancer
Genome Atlas (TCGA). Figure S1B shows that tTG transcript
levels are increased in the mesenchymal (45%) and classical
(16%) tumor subtypes.0, June 27, 2013 ª2013 The Authors 2009
Figure 2. tTG Is Essential for the Trans-
formed Characteristics of U87 and LN229
GBM Cells
(A) Soft agar colony-formation assays were per-
formed on U87, LN229, and T98G cells treated
without or with MDC or Z-Don. After 10 days of
growth, the colonies that formed were counted.
(B) U87, LN229, and T98G cells transfected with
control or tTG siRNAs were either lysed and
immunoblotted (IB) with tTG and actin antibodies
(insets) or subjected to soft agar colony-formation
assays. After 10 days of growth, the colonies that
formed were counted.
(C) Apoptotic assays were performed on U87,
LN229, and T98G cells cultured in serum-free
medium supplemented without or with MDC,
and without or with doxorubicin (Dox), for 1 day.
Apoptotic cells were identified by the presence of
condensed or blebbed nuclei.
Data are represented as mean ± SEM.
See also Figure S2.Overall, the trend we observed for tTG expression matched
that for EGFR expression and phosphorylation (Figure 1C, mid-
dle and right panels). Although we were not able to draw a strict
correlation between tTG expression and the survival of patients
with GBM (Figure 1D, left panel), we did find a correlation based
on tumor grade, similar to what has been observed for the EGFR
(Quaranta et al., 2007; Umesh et al., 2009). Individuals with gli-
omas of various grades whose tumors showed a 2-fold or
greater increase in tTG expression had an 25% reduction in
their expected lifespan, whereas those individuals with a 2-fold
or greater decrease in tTG expression benefited by an 20%
increase in their survival (Figure 1D, right panel).
tTG Is Essential for the Transformed Properties of GBM
Cell Lines
In order to learn more about the potential role played by tTG
in brain cancer, we set out to identify human GBM cell lines
that exhibited tTG-dependent transformed phenotypes. Three
commonly used human GBM cell lines, U87, LN229, and T98G
cells, were examined for tTG expression and acyltransferase
activity. As shown in Figure S1A, top panel, U87 and LN229 cells
exhibited significantly higher levels of tTG expression compared
to NHAs, whereas T98G cells exhibited only amodest increase in
tTG levels. The same was true when comparing the enzymatic
transamidation activity catalyzed by tTG in lysates prepared2010 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorsfrom these different cell lines, as readout
by assaying the incorporation of bio-
tinylated pentylamine (BPA) into their
lysate proteins (Figure S1A, bottom
panel) (Antonyak et al., 2004).
We next asked whether the expres-
sion of tTG in these GBM cells contrib-
uted to their ability to exhibit transformed
phenotypes. The anchorage-indepen-
dent growth of U87, LN229, and T98G
cells was assayed under conditionswhere tTG activity was blocked using two distinct tTG inhibitors,
mono-dansyl cadaverine (MDC) and Z-Don, or after tTG expres-
sion was knocked down by siRNA (Figures S2A and S2B). Fig-
ure 2A shows that the ability of both U87 and LN229 cells to
form colonies in soft agar was sensitive to MDC and Z-Don,
with the number of colonies formed by each of these cell lines
being reduced by at least 60% upon treatment with the
inhibitors. Likewise, the knockdown of tTG expression in U87
and LN229 cells using two different siRNAs (Figure 2B, insets)
inhibited colony formation (Figure 2B). In contrast, the
anchorage-independent growth of T98G GBM cells was not
dependent on tTG because it was insensitive to tTG inhibitors
MDC and Z-Don, as well as to siRNAs targeting tTG (Figures
2A and 2B).
It was previously shown that these brain cancer cells are resis-
tant to chemotherapy (Qian et al., 2012; Ren et al., 2010; Weaver
et al., 2003), and indeed, challenging the different GBM cell lines
with doses of doxorubicin that potently killed other types of
human cancer cells (i.e., SKBR3 breast cancer cells) (Antonyak
et al., 2004) induced only modest increases in cell death beyond
that normally observed in the absence of any treatment (Fig-
ure 2C). When assaying the survival of these GBM cell lines
following their exposure to various combinations of MDC and
doxorubicin, we found that MDC treatment alone caused little
or no increase in their rates of apoptosis (Figure 2C). However,
Figure 3. EGFR Signaling Is Potentiated in
U87 GBM Cells
(A) Extracts from U87 and T98G cells that had
been cultured in serum-free medium and then
further stimulated without or with EGF for
increasing lengths of time were immunoblotted
using a phospho-EGFR antibody (insets). The
relative activity of the EGFR in each cell line was
plotted (the EGFR activity detected at 10 min of
EGF stimulation was set as themaximal activity for
each cell line).
(B) Immunoprecipitations with an EGFR antibody
(IP: EGFR) were performed on the extracts from
U87 and T98G cells that had been cultured in
serum-free medium and then further stimulated
without or with EGF for 10 min. The resulting im-
munocomplexes were immunoblotted with EGFR
and ubiquitin antibodies, and the relative ubiq-
uitylation levels of the EGFR for each sample were
plotted (the level of EGFR ubiquitylation detected
in U87 cells stimulated with EGF for 10 min was
set as 1).
(C) Soft agar colony-formation assays were per-
formed on the T98G stable cell lines treated
without or with AG1478.
(D) Extracts from T98G cells stably expressing the
vector alone or a Myc-tagged wild-type tTG (tTG
WT) were immunoblotted with Myc, tTG, and actin
antibodies (top three panels), as well as assayed
for their enzymatic transamidation activity, as
readout by the incorporation of BPA into lysate
proteins (bottom panel).
(E) Extracts from the T98G stable cell lines
cultured in serum-free medium supplemented
without or with MDC were immunoblotted with
EGFR, tTG, and actin antibodies.
Data are represented as mean ± SEM in (A)–(C).when the cells were treated with both MDC and doxorubicin, an
2- to 3-fold increase in apoptosis occurred in U87 and LN229
cells compared to what was observed with doxorubicin alone
(Figure 2C, left and middle panels), whereas treatment of T98G
cells with the combination of MDC and doxorubicin showed
essentially no effect (Figure 2C, right panel). Together, these
findings demonstrate that the overexpression of tTG that occurs
in highly aggressive human brain tumors andGBM cell lines (U87
and LN229) strongly contributes to their aberrant growth and
chemoresistance.
tTG Regulates EGFR Levels and the Extent of
EGFR-Signaling Activities in Brain Tumor Cells
Both tTG and EGFR expression levels are frequently upregulated
in high-grade brain tumors. Thus, we examined whether EGFR
signaling might be enhanced and/or extended in a GBM cell
line that showed relatively high tTG expression and whose trans-
formed properties were dependent upon tTG (U87 cells),
compared to a cell line that expressed relatively low levels of
tTG and was not dependent upon it for transformation (T98G
cells). Indeed, we found that the signaling lifespans of activatedCEGFRs in U87 cells were extended, compared to the case for
T98G cells (Figure 3A). This appeared to be preceded by a signif-
icantly greater extent of EGFR ubiquitylation in T98G cells
compared to U87 cells (Figure 3B).
We then set out to establish that tTG is responsible for
enhancing EGFR signaling in GBM. First, we took advantage of
the fact that T98G GBM cells have relatively low levels of tTG
expression and are not dependent upon tTG for their survival
or transformed growth properties. Interestingly, these brain
cancer cells also showed virtually no dependence on EGFR
signaling for their transformed characteristics, as indicated by
their insensitivity to the EGFR tyrosine kinase inhibitor AG1487
(Figure 3C, compare the first and second histograms). We then
generated T98G cells that stably expressed either vector alone
or a Myc-tagged form of tTG (Figure 3D, top two panels). As ex-
pected, lysates from the cells overexpressing Myc-tagged tTG
exhibited significantly more transamidation activity than lysates
from cells expressing vector alone (Figure 3D, bottom panel).
Although T98G cells that expressed just the vector alone were
capable of forming colonies in soft agar, cells that ectopically
expressed tTG showed a significant increase (i.e., 2-fold) inell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authors 2011
Figure 4. tTG Regulates EGFR Levels and Signaling Activity in
GBM Cells
(A) Extracts from U87 and LN229 cells cultured in serum-free medium sup-
plemented without or with MDC for 1 day were immunoblotted using the
indicated antibodies. The fold changes in EGFR levels, as determined using
ImageJ, are highlighted.
(B) Extracts from U87 cells and LN229 cells expressing control or tTG siRNAs
were immunoblotted using EGFR, tTG, and actin antibodies. The fold changes
in EGFR levels, as determined using ImageJ, are highlighted.
(C) Extracts from U87 cells that had been cultured in serum-free medium and
then treated without or with MDC for 30 min before being further stimulated
with EGF for increasing lengths of time were immunoblotted using the indi-
cated antibodies.
See also Figure S3.their anchorage-independent growth (Figure 3C, compare the
first and third histograms). Moreover, upon ectopically express-
ing tTG in T98G cells, the EGFR protein levels increased by 3- to
4-fold (Figure 3E, top panel, compare the first and third lanes).
This increase in EGFR levels was offset upon treatment of the2012 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorscells with the tTG inhibitor MDC (Figure 3E, compare the third
and fourth lanes), thereby directly demonstrating that tTG influ-
ences EGFR expression. We then asked whether the ability of
tTG to potentiate EGFR levels in T98G transfectants was impor-
tant for the enhanced transforming capabilities exhibited by the
T98G cells stably overexpressing tTG. As shown in Figure 3C,
the enhanced colony formation exhibited by T98G cells upon
the ectopic expression of tTG was nearly completely eliminated
by AG1478 (compare the third and fourth histograms), indicating
that the enhancement in transformation accompanying overex-
pression of tTG was dependent upon EGFR tyrosine kinase
activity.
We then made use of the U87 and LN229 GBM cell lines to
further establish that tTG mediates the upregulation of EGFR
expression and signaling. Figure 4A (top two panels) shows
that treatment of both U87 and LN229 cells with the tTG inhibitor
MDC consistently reduced the basal levels of EGFR expression
and activation, as readout using an anti-pan-EGFR antibody and
an anti-phospho-EGFR antibody that detects EGFR autophos-
phorylation, respectively. Likewise, MDC treatment markedly
reduced the amount of EGFR-stimulated phosphorylation of
c-Jun, ERK, and Akt in both cell lines (Figure 4A, third, fifth,
and seventh panels), signaling outcomes occurring downstream
from the EGFR that are frequently observed in primary brain
tumors and brain tumor-derived cell lines, including U87 cells
(Figure S3A) (Antonyak et al., 2002; Hu et al., 2011; Mizoguchi
et al., 2006). To further confirm a role for tTG in regulating
EGFR expression levels, we examined whether a decrease in
the cellular steady-state levels of the EGFR accompanied
siRNA-mediated knockdowns of tTG. Indeed, the siRNA-
induced reduction in tTG levels by 80% in U87 cells and
50% in LN229 cells (Figure 4B, second panels from the top)
resulted in corresponding decreases in EGFR expression (Fig-
ure 4B, top panels).
We next examined whether tTG influenced the extent of
EGFR-signaling activities in these GBM cells. Serum-starved
cultures of U87 cells were treatedwith EGF for increasing lengths
of time, in the presence or absence of MDC. Figure 4C shows
that a maximal activation of EGFR tyrosine kinase activity
occurred within 10 min of growth factor treatment (top panel).
EGF stimulation of U87 cells pretreated with MDC showed a
marked reduction in the magnitude of EGFR activation. Cell sur-
face biotin-labeling experiments performed on the cells showed
that this was due to reductions in the EGFR levels at the plasma
membrane (Figure S3B). Moreover, the phosphorylation of c-Jun
(Figure 4C, second panel from the top) and ERK (Figure 4C, third
panel from the top) was significantly reduced in U87 cells pre-
treated with MDC. Although each of these signaling events
showed little dependence on EGF stimulation, the basal activ-
ities of both were dependent on EGFR activity as indicated by
the inhibition caused by the specific EGFR tyrosine kinase inhib-
itor AG1478 (Figure S3A). EGFR activation was also compro-
mised in LN229 GBM cells treated with the tTG inhibitor MDC
(Figure S3C).
We also examined whether tTG could influence the levels of
the EGFR variant type III (EGFRvIII), a commonly occurring and
highly oncogenic mutant form of the EGFR that is defective in
its downregulation (Huang et al., 2009). Figure S3D shows that
Figure 5. tTG Influences the Ubiquitylation
of the EGFR by Associating with
E3 Ubiquitin Ligase c-Cbl
(A) Immunoprecipitations with an EGFR antibody
were performed on the extracts from U87 cells
that were cultured in serum-free medium supple-
mented without or with MDC or Z-Don for 1 day.
The resulting immunocomplexes as well as
samples of the whole-cell lysates (WCLs) were
immunoblotted with EGFR, ubiquitin, tTG, and
actin antibodies. The fold changes in ubiquitylated
EGFR, as determined using ImageJ, are high-
lighted.
(B) Immunoprecipitations with an EGFR antibody
were performed on the extracts from U87 cells
expressing control or tTG siRNAs. The resulting
immunocomplexes were then immunoblotted with
EGFR and ubiquitin antibodies.
(C) Immunoprecipitations with an HA antibody
(IP: HA-c-Cbl) were performed on extracts
from U87 cells transfected with HA-tagged
c-Cbl (HA-c-Cbl) and cultured in serum-free
medium supplemented without or with MDC
for 1 day. The resulting immunocomplexes,
as well as the whole-cell extracts collected
(WCLs), were immunoblotted with tTG and HA
antibodies.
(D) List of the various tTG constructs used
in this study, including the name of each
construct, the sites of the mutations, and their
functional consequences on nucleotide bind-
ing and enzymatic transamidation activity are
indicated.
(E) Immunoprecipitations with an HA antibody
were performed on extracts from U87 cells
transfected with HA-tagged c-Cbl and either
Myc-tagged wild-type tTG (Myc-tTGWT) or one of
the indicated Myc-tagged mutant forms of tTG
listed in (D). The resulting immunocomplexes, as
well as the whole-cell extracts collected (WCLs),
were immunoblotted with HA, Myc, and actin
antibodies.
(F) Purified, recombinant His-tagged, wild-type
(WT) tTG, or one of the mutant forms of tTG, was
incubated alone or together with an equal amount
of recombinant GST-tagged c-Cbl. The resulting
protein complexes were precipitated with GST
beads and then immunoblotted with tTG and c-Cbl antibodies (Pull-down: GST). Each form of His-tagged tTG used in the pull-down assay was also
immunoblotted with a tTG antibody to confirm that equal amounts of recombinant tTG were used in the experiment (Input).
See also Figure S4.ectopic EGFRvIII expression in U87 cells was not affected by
MDC treatment (compare the first and second lanes to the third
and fourth lanes). This suggests that tTG is not important for
extending the lifespan of this mutant EGFR, most likely because
unlike the wild-type EGFR, this truncated EGFR variant has an
inherent insensitivity to the degradative actions of c-Cbl (Han
et al., 2006; also, see below).
tTG Blocks Ubiquitylation of the EGFR
Taken together, the results presented in Figures 3 and 4, as well
as those shown in Figure 5A, left panel, suggest that the actions
of tTG are directed at enhancing the stability of wild-type EGFRs.
The ubiquitylation-mediated downregulation of the EGFR, asCcatalyzed by the E3 ubiquitin ligase c-Cbl, plays an essential
role in terminating EGFR-signaling activities by targeting the
receptor for degradation in the lysosomes (Levkowitz et al.,
1998; Waterman et al., 1999). Figure 5A, right panel, shows
that following treatment of U87 cells with MDC or Z-Don, the
amount of detectable ubiquitylation of the immunoprecipitated
EGFR was enhanced, compared to an equivalent amount of
EGFR immunoprecipitated from untreated cells. It is worth
noting that the overall levels of ubiquitylated proteins in U87 cells
were largely unaffected byMDCor Z-Don treatment (FigureS4A),
suggesting that the changes in the ubiquitylation status of the
EGFR caused by tTG represented a specific regulatory event.
Similar increases in EGFR ubiquitylation were observed whenell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authors 2013
tTG expression was knocked down by siRNAs in U87 cells (Fig-
ure 5B) or when LN229 cells were exposed to MDC (Figure S4B).
In an effort to understand the molecular mechanism by which
tTG inhibits EGFR ubiquitylation, we examined whether tTG
might be capable of associating with c-Cbl in cells. Figure 5C
shows that endogenous tTG can be coimmunoprecipitated
with HA-tagged c-Cbl from U87 cells. This interaction was
greatly reduced when the cells were treated with MDC. Based
on these findings, our initial assumption was that the acyltrans-
ferase or transamidation activity of tTG was in some way
involved in its ability to associate with and/or negatively regulate
the function of c-Cbl. Such an idea was consistent with several
findings that suggested that the enzymatic transamidation activ-
ity of tTG was necessary for mediating many of its effects in cells
(Antonyak et al., 2004; Datta et al., 2006; Verma et al., 2006).
We therefore set out to further examine this possibility by
using various tTG mutants that we have developed in the labo-
ratory (Figure 5D). The results in Figure 5E (panels on the right)
show that a Myc-tagged wild-type tTG construct was capable
of associating with HA-tagged c-Cbl, similar to what we had
observed with endogenous tTG, whereas a transamidation-
defective mutant, tTG C277V, in which the active site cysteine
residue had been changed to a valine (Li et al., 2010), was inca-
pable of being coimmunoprecipitated with c-Cbl. This seemed
to support the suggestion that the transamidation activity of
tTG was involved in the interaction. However, surprisingly, we
found that another tTG mutant, tTG D306N, N310A (referred
to as the ‘‘Site II mutant’’), which was incapable of catalyzing
transamidation because of two substitutions at one of the
major Ca2+-binding sites essential for catalysis (Datta et al.,
2006), was able to associate with c-Cbl (Figure 5E, panels on
the right). Moreover, a GTP-binding-defective tTG mutant (tTG
R580K), which exhibits greatly enhanced transamidation activity
because its enzymatic activity is not subject to the same
negative regulation that accompanies the binding of GTP to
wild-type tTG (Datta et al., 2007), was incapable of associating
with c-Cbl. Collectively, these results ruled out the possi-
bility that the transamidation activity of tTG was required for
its ability to associate with and inhibit the E3 ubiquitin ligase
activity of c-Cbl.
We then asked whether the ability of tTG to associate with
c-Cbl in cells was the outcome of a direct binding interaction.
Purified recombinant, His-tagged wild-type tTG, as well as
different tTG mutants, was incubated with purified recombinant
GST-c-Cbl and then the proteins were examined for complex
formation by precipitating the GST-c-Cbl with glutathione-
coated agarose beads. Figure 5F (first lane) shows that His-
tagged wild-type tTG was coprecipitated with GST-c-Cbl,
indicating that these proteins undergo a direct binding interac-
tion. Likewise, the recombinant His-tagged tTG Site II mutant
was able to bind GST-c-Cbl, whereas His-tagged tTG R580K
and His-tagged tTG C277V were ineffective (Figure 5F), consis-
tent with our coimmunoprecipitation data in cells.
The GTP-Bound ‘‘Closed’’ Form of tTG Is Responsible
for Inhibiting c-Cbl Function
We next examined whether the GTP-binding activity of tTG is
involved in its ability to associate with c-Cbl. The GTP-binding2014 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorscapabilities of the different tTG mutants, relative to the wild-
type protein, were assayed by taking advantage of the ability
of the fluorescent GTP analog, BODIPY-GTP, to rapidly bind
tTG and undergo a significant change in its fluorescence emis-
sion (Datta et al., 2007). Figure 6A shows that, like the case for
wild-type tTG (top-left panel), BODIPY-GTP was capable of
rapidly associating with the tTG Site II mutant (top-right panel),
with the binding being sustained until the addition of unlabeled
GTPgS, which caused a rapid reversal of the interaction with
the labeled GTP analog. BODIPY-GTP also showed a rapid
association with the tTG C277V mutant (Figure 6A, bottom-left
panel); however, this was followed by a steady dissociation of
the labeled GTP analog, indicative of a much weaker interaction
compared to either wild-type tTG or the tTG Site II mutant.
The tTG R580K mutant showed essentially no ability to bind
BODIPY-GTP (Figure 6A, bottom-right panel), consistent with
our earlier studies that showed this mutant to be GTP-binding
defective (Datta et al., 2007).
X-ray crystallographic studies have shown that tTG can exist
in two distinct conformational states. When bound to guanine
nucleotide (i.e., GTP bound in cells), tTG adopts what is referred
to as a closed conformational state where the b1 and b2 barrel
domains fold over the central core of the protein that contains
the transamidation catalytic site (Liu et al., 2002) (Figure 6B,
left side). However, in the absence of bound GTP, the protein
assumes a more extended or ‘‘open’’ conformation in which
the catalytic site is fully accessible (Figure 6B, right). This was
first shown when the X-ray structure was solved for tTG bound
to a peptide that mimics the inflammatory gluten peptide sub-
strate that binds to the transamidation active site (Pinkas et al.,
2007). Thus, when the structural data are taken together with
the results of the coimmunoprecipitation and GST pull-down
experiments presented in Figures 5E and 5F, as well as the
GTP-binding data in Figure 6A, it would appear that it is the
GTP-bound, closed state of tTG that is best suited for associ-
ating with and functionally inactivating c-Cbl.
Further support for this idea came from studies where we
examined the protease sensitivity of wild-type tTG and the
different tTG mutants. Figure 6C shows that wild-type tTG, and
the tTG Site II mutant, exhibited similar capabilities for resisting
trypsin proteolysis, whereas the tTG C277V mutant behaved in
a similar manner to the GTP-binding-defective tTG R580K
mutant and was highly sensitive to protease treatment. This indi-
cates that the tTG Site II mutant adopts an overall conformation
similar to that of the GTP-bound, wild-type protein, as indicated
by its ability to resist trypsin proteolysis, whereas the tTG C277V
mutant assumes a conformation more like that of the GTP-bind-
ing-defective tTG R580K mutant. Interestingly, we found that
MDC, in a dose-dependent manner, enhanced the protease
sensitivity of wild-type tTG, thus causing it to behave more like
the tTG R580K and tTG C277V mutants (Figure 6D). These find-
ings might then explain why MDC treatment inhibits the ability of
tTG to interact with c-Cbl, as readout in coimmunoprecipitation
experiments (Figure 5C). Specifically, rather than weakening the
interaction between tTG and c-Cbl by blocking access to the
transamidation active site of tTG, the binding of the inhibitor
helps tTG to assume a more open conformation that has very
weak affinity for c-Cbl.
Figure 6. tTG Adopts Distinct Conforma-
tions Depending on whether It Is Bound to
GTP
(A) Purified recombinant forms of wild-type tTG,
tTG C227V, tTG R580K, and the tTG Site II mutant
were incubated with BODIPY-GTP, and the
resulting changes in fluorescence caused by the
binding of BODIPY-GTP to the proteins were
determined. The asterisk (*) indicates the point in
the assay when an excess of unlabeled GTPgS
was added to the tTG proteins to compete off
BODIPY-GTP.
(B) X-ray crystal structures and schematic repre-
sentations of the closed and open conformations
of tTG. tTG adopts a closed conformation when it
is bound to GDP (PDB 1KV3) (left side) or an open
conformation when it is in a nucleotide-free state
(PDB 2Q3Z). The domains highlighted in the tTG
diagrams include the N-terminal b sandwich (N),
the catalytic core (core), and the two C-terminal
b barrels (b1 and b2).
(C) Purified recombinant forms of wild-type tTG,
tTG C277V, tTG R580K, and tTG Site II (3.0 mg of
each protein) were incubated without or with
trypsin for 2 hr before being resolved by SDS-
PAGE and then stained with Coomassie blue to
visualize the proteins.
(D) Purified recombinant wild-type tTG (3.0 mg)
pretreated without or with increasing amounts of
MDC was incubated with trypsin for 2 hr before
being resolved by SDS-PAGE and then stained
with Coomassie blue to visualize the proteins.The relative effectiveness of these different mutants to asso-
ciate with c-Cbl could be correlated with their effects on EGFR
activation (autophosphorylation) and receptor ubiquitylation.
Figure 7A shows that when the different mutants were transiently
expressed in U87 cells as Myc-tagged proteins, both wild-type
tTG and the Myc-tTG Site II mutant were able to increase the
levels of activated EGFR upon EGF treatment, whereas the
Myc-tTG C277V mutant and the GTP-binding-defective Myc-
tTG R580K mutant were completely ineffective. Although we
were not able to make reliable comparisons of the effects of
the different mutants on EGFR ubiquitylation in U87 cells, we
were able to compare their actions in the human breast cancer
cell line SKBR3, which lacks endogenous tTG expression. The
results of these experiments suggested that only wild-type tTG
and the tTG Site II mutant were able to reduce EGFR ubiquityla-
tion (Figure 7B), which was fully consistent with their abilities to
associate with c-Cbl.Cell Reports 3, 2008–202DISCUSSION
In this study, we set out to gain new
insights into the molecular mechanisms
contributing to the development of malig-
nant gliomas. These efforts led us to tTG,
a GTP-binding protein and Ca2+-depen-
dent acyltransferase, whose expression
is upregulated in several types of cancer
(Li et al., 2010;Miyoshi et al., 2010; Vermaet al., 2006). We show that this is also true for malignant gliomas.
Although the levels of tTG were consistently low in normal brain,
as well as in most grade I and II tumors, tTG expression was
noticeably upregulated in the more aggressive, high-grade (i.e.,
grades III and IV) tumors. In fact, we found that it was overex-
pressed in 70% of these cases, making the upregulation of
tTG expression one of the most frequently occurring events in
human brain tumors. Moreover, there appears to be a correlation
between the increased expression of tTG in brain cancer and a
poor survival prognosis for patients.
A number of studies have implicated tTG in cancer cell growth,
chemoresistance, invasiveness, and metastasis (Li et al., 2011;
Verma et al., 2006) and to be a downstream signaling partner
of the EGFR (Antonyak et al., 2009; Boroughs et al., 2011; Li
et al., 2010). Its involvement in EGFR signaling was particularly
intriguing to us because EGFR overexpression and activating
EGFR mutations are recurring themes in human cancer and0, June 27, 2013 ª2013 The Authors 2015
Figure 7. Ectopic Expression of tTG Forms
that Are in the Closed Conformation
Enhances EGFR Signaling
(A) Cell extracts from U87 cells ectopically
expressing the vector alone, wild-type tTG (Myc-
tTG WT), or one of the different mutant forms of
tTG stimulated without or with EGF (100 ng/ml) for
20 min, were immunoblotted using phospho-
EGFR, Myc, and actin antibodies.
(B) Immunoprecipitations with an EGFR antibody
were performed on the cell extracts from SKBR3
cells transfected with wild-type (Myc-tTG WT) or
one of the different mutant forms of tTG indi-
cated. The resulting immunocomplexes were
then immunoblotted with ubiquitin and EGFR
antibodies.
(C) Schematic representation depicting the effects
of tTG on EGFR signaling. In normal conditions,
c-Cbl is recruited to the activated EGFR and me-
diates its ubiquitylation. The ubiquitylated EGFR is
then endocytosed and targeted for degradation in
the lysosome. In brain tumor cells where tTG is
abundantly expressed, tTG forms a complex with
c-Cbl and prevents it from ubiquitylating the
EGFR. This disrupts the normal downregulation of
the EGFR, extending its signaling lifespan and
enhancing cellular transformation.
See also Figure S5.are especially important for the aggressive phenotypes exhibited
by high-grade primary brain tumors (Frederick et al., 2000;
Huang et al., 2009; Layfield et al., 2006). In fact, overexpression
of the EGFR has been reported in a large majority of the high-
grade (grade IV) tumors or GBMs, whereas it is rarely seen in
the lower-grade I and II brain tumors. Consequently, EGFR sta-
tus is considered to be a prognostic indicator for patients with
brain tumors (Jung et al., 2012; Quaranta et al., 2007; Shinojima
et al., 2003).
It has been well established that the amplification of the gene
encoding the EGFR represents one common mechanism
through which EGFR expression levels are increased in GBMs
(Layfield et al., 2006). However, 10%–30% of brain cancers
that show high EGFR expression contain a normal receptor
gene copy number. Therefore, additional mechanisms must
account for the relatively high EGFR protein levels and enhanced
EGFR signaling observed in some brain cancers (Huang et al.,
2009). In light of these findings, we began to consider the idea
that a previously unappreciated functional interplay might exist
among tTG, the EGFR, and brain tumor progression. This in
fact turned out to be the case. We now describe how tTG helps
maintain EGFR protein levels in GBMs, enhancing the extent and2016 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorslifespan of EGFR activation and down-
stream signaling activities, through a
mechanism that does not involve gene
amplification but, rather, is due to the
ability of tTG to interfere with receptor
ubiquitylation and degradation that are
normally catalyzed by the EGFR-adaptor
protein and negative regulator, c-Cbl.Work by Vivanco et al. showed that PTEN loss can result in a
diminished c-Cbl-dependent degradation of EGFRs (Vivanco
et al., 2010). Because previous studies from our laboratory
showed that the PI3K/Akt pathway is necessary for the upregu-
lation of tTG expression in breast cancer cells upon growth
factor treatment (Li et al., 2010), we asked whether the inactiva-
tion of PTEN could regulate tTG levels and that perhaps changes
in tTG expression could explain the effects of PTEN on EGFR
degradation. Consistent with previous reports, U87 cells contain
a truncated version of PTEN, LN229 cells express wild-type
PTEN, and T98G cells contain PTEN harboring a point mutation
(Furnari et al., 1997). However, although an inverse correlation
appears to exist between the expression levels of tTG and
PTEN in the different GBM cells that we examined (Figure S5A),
we did not observe any significant change in the levels of tTG
when we ectopically expressed increasing amounts of PTEN in
U87 cells (Figure S5B) or mimicked PTEN function by inhibiting
downstream signaling events with a PI3K inhibitor LY294002
(Figure S5C), suggesting that upregulation of tTG in these brain
cancer cells is not due to inactivation of PTEN.
tTG is best known for its enzymatic, Ca2+-dependent acyl-
transferase activity that catalyzes the crosslinking of proteins
through the formation of covalent linkages between glutamine
residues on ‘‘acceptor’’ proteins and lysine residues on ‘‘donor’’
proteins (Li et al., 2011). However, interestingly, tTG is also
capable of binding and hydrolyzing GTP similar to other classical
G proteins (Li et al., 2011). These two activities are reciprocally
regulated, such that GTP-bound tTG exhibits little detectable
transamidation activity, whereas millimolar levels of Ca2+
weaken GTP binding to tTG and thereby stimulate its enzymatic
activity. This would imply that intracellular tTG exists in its GTP-
bound state, given the high cellular concentrations of GTP and
typically low concentrations of Ca2+, whereas upon its secretion,
tTG may then be capable of catalyzing protein crosslinking
events. In fact, as schematized in Figure 7C and discussed
further below, our data suggest that it is the GTP-bound, closed
state of tTG that is responsible for preventing c-Cbl from exerting
its negative regulatory effects on the EGFR.
Two key findings have provided us with a mechanistic picture
of how tTG blocks the actions of c-Cbl and thereby helps main-
tain EGFR protein levels in GBM cells. U87 and LN229 human
GBM cell lines are highly dependent on EGFR signaling for their
transformed phenotypes. Interestingly, these cell lines also
express inordinately high levels of tTG. Moreover, when tTG
expression was knocked down in these cells by siRNA, corre-
sponding reductions were observed in the expression and acti-
vation of the EGFR, as well as in the transforming capabilities
of these cancer cell lines.
Perhaps even more striking were the results from experiments
that took advantage of the unique qualities of the T98G GBM cell
line. Unlike U87 and LN229 cells, T98G cells are not dependent
on the EGFR for their transforming potential. Moreover, they do
not express, nor are they dependent upon, tTG for their trans-
formed properties. However, when a Myc-tagged form of tTG
was stably introduced into these cells, EGFR expression was
increased between 3- and 4-fold compared to the vector alone
expressing control cells. Importantly, T98G cells overexpressing
tTG were capable of forming nearly twice as many colonies in
soft agar as their control counterparts, an outcome that was
dependent on the enhanced EGFR activity associated with these
cells. Thus, these findings demonstrate that the overexpression
of tTG in at least certain brain tumor cell lines is sufficient to
maintain relatively high EGFR levels and exacerbate their trans-
formed phenotypes. Because tTG is overexpressed in several
additional types of human cancer (i.e., breast, ovarian, and
pancreatic cancer), it will be interesting to see whether this inter-
play between tTG and the EGFR holds up in these cancer types
as well.
How does tTG have such profound effects on the actions of
c-Cbl and, consequently, EGFR expression in GBMs? Given
that knockdown of tTG expression in U87 and LN229 cells, as
well as the treatment of these cells with the tTG crosslinking
inhibitor MDC or Z-Don, markedly increased the amounts of
ubiquitylated EGFRs, we had initially assumed that the transami-
dation activity of tTG was responsible for its ability to inactivate
the E3 ubiquitin ligase activity of c-Cbl. However, a careful anal-
ysis of the interaction of tTG with c-Cbl revealed that it did not
rely upon, and indeed occurred independently of, tTG’s transa-
midation activity but, instead, appeared to be dependent on its
GTP-binding capability. This is especially interesting in light ofCstructural studies that show that the binding of GTP to tTG
causes the protein to adopt a ‘‘closed conformation’’ that main-
tains it in an enzymatically inactive state by blocking substrate
access to the catalytic domain. Under conditions of high Ca2+
(as might occur when tTG is extracellular), GTP dissociates,
and tTG adopts an ‘‘open conformation’’ in which the transami-
dation active site is accessible and able to catalyze the crosslink-
ing of proteins. Thus, the only mutant form of tTG that constitu-
tively adopts the closed state (i.e., Site II mutant) is capable of
binding to c-Cbl and blocking its ability to catalyze EGFR ubiqui-
tylation. The ability of MDC treatment to block tTG from protect-
ing the EGFR from c-Cbl-mediated ubiquitylation is most likely
an outcome of this competitive tTG inhibitor causing the protein
to adopt an open conformation that has weak affinity for c-Cbl.
Similarly, the X-ray structure for Z-Don covalently linked to the
active site cysteine of tTG (Protein Data Bank [PDB] 3S3J) shows
that the inhibitor-tTG complex adopts an open conformation,
consistent with the ability of Z-Don to block the protective effects
of tTG. Therefore, we believe that it is the GTP-bound, closed
state of tTG, perhaps acting in a manner analogous to classical
signaling G proteins, that enables it to associate with c-Cbl
and thereby provides a unique mode of regulation of EGFR
expression (Figure 7C).
In closing, we have identified a mechanism where through the
actions of tTG, relatively high EGFR protein levels can be main-
tained, and EGFR-signaling activities enhanced and extended in
human brain tumors, thus contributing to their oncogenic pheno-
types. Given that a number of therapeutic strategies directed at
blocking EGFR activation and function, primarily through the use
of tyrosine kinase inhibitors and monoclonal antibodies, have
only had limited success in the clinics, there remains an over-
riding need to develop approaches that target the EGFR. Our
finding that tTG is frequently overexpressed in high-grade brain
tumors, coupled with the fact that it interferes with the proper
downregulation of the EGFR, raises the interesting possibility
that developing approaches that block the ability of tTG to
interact with c-Cblmay offer potentially strategies for therapeutic
intervention.EXPERIMENTAL PROCEDURES
Materials
Cell culture reagents, EGF, Lipofectamine, Lipofectamine 2000, Protein G
agarose beads, and the control and tTG siRNAs were obtained from Invitro-
gen. G418, MDC, AG1478, and doxorubicin were from Calbiochem. Z-Don
was from Zedira, and BPA was from Pierce. Antibodies for tTG and actin
were purchased from Thermo Fisher Scientific. Antibodies for EGFR, phos-
pho-EGFR, phospho-Akt, Akt, phospho-c-Jun, c-Jun, phospho-ERK, ERK,
PTEN, and phospho-PTEN were from Cell Signaling Technology. Ubiquitin
and c-Cbl antibodies were from Santa Cruz Biotechnology, and HA and Myc
antibodies were from Covance. Avidin/Biotin blocking solutions, Elite ABC
reagent, and chromogen solution for immunohistochemical analysis were
obtained from Vector Laboratories.
Cell Culture, Transfections, and Inhibitor Treatments
U87 and SKBR3 cells were maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), the LN229 and T98G cells were maintained
in DMEM supplemented with 10% FBS, whereas NHAs were maintained in
AGM (Lonza) supplemented with the BulletKit (Lonza). The expression con-
structs were introduced into cells using Lipofectamine, whereas the controlell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authors 2017
and tTG siRNAs were introduced into cells using Lipofectamine 2000. T98G
cells stably expressing the vector alone or Myc-tagged tTG were selected
by supplementing the growth medium with 1 mg/ml G418. Where indicated,
cells were treated with 50 mM MDC, 50 mM Z-Don, 10 mM AG1478, 1.0 mM
doxorubicin, and 100 ng/ml EGF.
Tumor Analysis
Tissue array slides composed of paraffin-embedded sections of normal brain
samples and human primary brain tumors of various grades (#GL208; US Bio-
max) were subjected to immunohistochemical analysis. Briefly, the slides were
deparaffinized by baking them at 60C for 30 min and then rehydrating them in
water containing 3% hydrogen peroxide for 30 min. After washing with PBS,
the slides were boiled for 10 min in a 10 mM sodium citrate buffer (pH 6.0)
and allowed to cool. The slides were then blocked with 2.5% horse serum
and with Avidin/Biotin blocking solutions. The tissue arrays were incubated
with a tTG, EGFR, or phospho-EGFR antibody, followed by a biotinylated sec-
ondary antibody and treatment with the Elite ABC reagent for 30 min. After
washing with PBS, the slides were processed with chromogen solution.
Finally, the slides were dehydrated and mounted. The resulting staining
obtained with each antibody was quantified using ImageJ software.
REMBRANDT Analysis
The REMBRANDT (Repository of Molecular Brain Neoplasia Data) database
(https://caintegrator.nci.nih.gov/rembrandt/) was used to correlate tTG
expression levels in brain tumors with patient survival rates. The parameters
were set to include those brain tumor samples (343 gliomas or 181 GBMs)
with a 2-fold or greater increase or a 2-fold or greater decrease in tTG expres-
sion. The results were presented as Kaplan-Meier survival plots.
TCGA Analysis
tTG transcript levels in GBM patient samples deposited in TCGA (https://
tcga-data.nci.nih.gov/tcga/) were analyzed using the cBio Cancer Genomics
Portal (Z score of 0.5). The percentage of patients with increased tTG levels
was plotted for each GBM subtype.
Immunoblot Analysis and Immunoprecipitation
Cells were lysed with cell lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton
X-100, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM Na3VO4, 1 mM b-glycer-
olphosphate, 1 mg/ml leupeptin, and 1 mg/ml aprotinin). The extracts were
resolved by SDS-PAGE and transferred onto PVDF membranes. The mem-
branes were incubated with primary antibodies diluted in TBST (20 mM Tris,
135 mM NaCl, and 0.02% Tween 20). Horseradish peroxidase (HRP)-conju-
gated secondary antibodies were used to detect the primary antibodies
followed by exposure to ECL reagent. For immunoprecipitations, cell extracts
(600 mg) were incubated with a particular antibody for 2 hr, followed by the
addition of Protein G beads for 1 hr. The beads were washed with cell lysis
buffer before being subjected to immunoblot analysis.
Soft Agar Colony-Formation Assays
Cells (3 3 103) were suspended in growth medium supplemented without or
with the indicated inhibitors and 0.3% agarose and plated on top of a layer
of growth medium containing 0.6% agarose in a six-well plate. The growth
medium and inhibitors were replenished on the cultures every fourth day,
and, after 10 days of growth, the colonies that formed were counted and
graphed.
Apoptotic Assays
Cultures of cells were placed in serum-free medium containing various combi-
nations of doxorubicin and MDC. After 1 day, the cells were collected and
stained with DAPI for visualization by fluorescence microscopy. Cells under-
going apoptosis were identified by nuclei condensation/blebbing.
Transamidation Activity Assays
Cell extracts (15 mg of each) were incubated in a buffer containing 10 mMDTT,
10 mMCaCl2, and 50 mMBPA for 10 min. The reactions were stopped with the
addition of Laemmli sample buffer, followed by boiling, and then the proteins
were resolved by SDS-PAGE, transferred to PDVF membranes, and blocked2018 Cell Reports 3, 2008–2020, June 27, 2013 ª2013 The Authorsovernight in BBST (100 mM boric acid, 20 mM sodium borate, 0.01% SDS,
0.01% Tween 20, and 80 mM NaCl) containing 10% BSA. The membranes
were incubated with HRP-conjugated streptavidin, diluted at 1:2,000 in
BBST containing 5% BSA for 1 hr, followed by extensive washing with
BBST. The proteins that incorporated BPA were visualized on X-ray film after
exposing the membranes to ECL reagent.
Cell Surface Protein-Isolation Assays
Cell surface EGFR was isolated using the cell surface protein-isolation kit
according to the manufacturer’s protocol (Pierce). Briefly, U87 cells exposed
to different culturing conditions were incubated with a cell-impermeable
biotinylation reagent that labels the exposed primary amines of proteins
expressed on the cell surface before being lysed. The EGFR was then immu-
noprecipitated from the extracts, and the cell surface EGFR was detected
using HRP streptavidin.
BODIPY-GTP-Binding Assays
Recombinant tTG (600 nM final concentration) was added into buffer contain-
ing 1 mM BODIPY-GTP, 50 mM Tris-HCl, 2 mM DTT, and 1 mM EDTA. Fluo-
rescence changes were measured using a Varian eclipse spectrofluorometer.
The excitation and emission wavelengths for BODIPY fluorescence were set at
504 and 520 nm, respectively.
Trypsin Digestion Assays
The recombinant tTG proteins (3 mg of each) were combined with 80 ng of
trypsin in a buffer containing 20 mM Tris, 300 mM NaCl, and 10% glycerol.
The reaction was carried out on ice for 2 hr and stopped with the addition of
Laemmli sample buffer, followed by boiling. The proteins were then resolved
by SDS-PAGE, and the gels were stained with Coomassie blue to visualize
the proteins.
In Vitro Binding Assays
Purified, recombinant His-tagged, wild-type tTG, or one of the mutant forms of
tTG, was combined without or with purified, GST-tagged c-Cbl (1.0 mg of each
protein) in a tube and rotated at 4C for 2 hr. Glutathione-coated agarose
beads were then added to each tube for an additional 60 min, at which time
the precipitated complexes were subjected to immunoblot analysis using
tTG and c-Cbl antibodies.
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